Beactica’s drug discovery platform delivers promise for brain tumour therapy

Beactica's CEO, Dr Per Källblad, explains how the company’s specialist small molecule drug discovery platform is developing a novel therapy for glioblastoma. 

Read full article here.

See all recent coverage